Updates from the 2014 San antonio breast cancer symposium.

Indian J Med Paediatr Oncol · 2015 · PMC4363856 · PMID 25810580

Europe PMC DOI

hedged sentence

0.0440

closest p · 0.9× alpha

0.0440

boldest claim

The sentences

did not reach statistical significanceP = 0.044actually significant

However in the subgroup with HER2 positive, hormone receptor negative breast cancer the addition of everolimus resulted a 7 months improvement in progression free survival (20 mos with everolimusvs 13 mos with placebo; HR: 0.66; P =.0049) but this did not reach statistical significance threshold based on trial design ( P = 0.044).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.